Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis

References

• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chi-meric anti-TNF- a monoclonal antibody cA2 binds recombinant transmembrane TNF- a and activates immune effector functions. Cytokine. 1995;7: 251–9.
   Google Scholar
• Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995;7:15–25.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adafimumab. Arthritis Rheum. 2008;58:1248–57.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 2007;337: 1029–35.
   Google Scholar
• Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, et al. Tumor necrosis factor alpha antibody (inf-liximab) therapy profoundly down-regulates the inflammation in Crohn's ileocofitis. Gastroenterology. 1999;116:22–8.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis. 2005;64(Suppl 4):31–6.
   Google Scholar
• Brandt J, Haibel H, Comely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody inflix-imab. Arthritis Rheum. 2000;43:1346–52.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357: 1842–7.
   PubMed Web of Science ®Google Scholar
• CalM A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:1594–600.
   Google Scholar
• Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with pso-riasis. N Engl J Med. 2003;349:2014–22.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1998;31:315–24.
   Web of Science ®Google Scholar
• Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
   Google Scholar
• Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Com-parison of disease activity score (DAS)28-erythrocyte sedi-mentation rate and DA528-C-reactive protein threshold values. Ann Rheum Dis. 2007;66: 407–9.
   Google Scholar
• Temant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. 'Ther Drug Monit. 2006;28:169–74.
   PubMedGoogle Scholar
• Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601–8.
   Google Scholar
• Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nur-mohamed MT, Stapel S, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–5.
   PubMed Web of Science ®Google Scholar
• Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 2006;33:31–6.
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3–10.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized con-trolled trial. Gastroenterology. 2003;124:917–24.
   PubMed Web of Science ®Google Scholar
• de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:531–5.
   Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–7.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:353–63.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multi-center, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 2008;58: 1921–30.
   Google Scholar
• Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of eta-nercept liquid administered once weekly in patients with rheu-matoid arthritis. Clin Exp Rheumatol. 2007;25:40–6.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-con-trolled trial. Ann Rheum Dis. 2008;67:1516-23 (erratum in: Ann Rheum Dis. 2009;68: 296).
   Google Scholar